Notice of Closed Meeting, 2703-2704 [2025-00492]
Download as PDF
<![CDATA[
Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
U.S. consumers and businesses,
including for-profit and not-for-profit
enterprises, and federal, state, and local
government agencies. The aggregate
estimates produced from the survey data
are widely cited in academic working
papers, journal articles, and industry
publications; reported in the media; and
used by the public, industry, and policy
makers as a quantitative aggregate
benchmark of noncash payments and
cash withdrawal and deposit activity in
the United States.
Frequency: Annually.
Respondents: Organizations with a
significant role in processing payments,
including depository and financial
institutions, general-purpose payment
networks, third-party payment
processors, issuers of private-label
payment instruments, and providers of
various alternative payment methods
and systems.
Total estimated number of
respondents: FR 3066a, 513, FR 3066b,
170.
Estimated average hours per response:
FR 3066a, 22; FR 3066b, 8.
Total estimated annual burden hours:
12,646.
Current actions: On July 30, 2024, the
Board published a notice in the Federal
Register (89 FR 61116) requesting
public comment for 60 days on the
extension, without revision, of the FR
3066. The comment period for this
notice expired on September 30, 2024.
The Board received one comment.
Detailed Discussion of Public
Comments
The Board received one public
comment from a payments industry
association. The commenter was
supportive of renewing and continuing
this information collection. The
commenter also urged the Board to
publish timely and comprehensive
results from the FRPS.
The Board strives to release detailed
results from the FRPS expeditiously.
Both the Board and FRB Atlanta are
working continuously to improve both
the quality and the timing of FRPS
releases. The Board intends to publish
any releases as soon as practicable with
the goal of making information available
while not sacrificing the quality and
accuracy of that information. Achieving
the necessary quality standard for
detailed data is particularly important
when constructing national estimates
upon which policymakers, the industry,
and the public can rely.
To that end, the Board expects to
continue the practice of releasing results
in stages, with an initial release of
topline estimates followed by more
extensive detailed releases at a later
VerDate Sep<11>2014
18:48 Jan 09, 2025
Jkt 265001
stage. Results from annual supplements
will periodically complement the initial
and detailed triennial releases. Focused
reports or releases on specific topics
may also be published periodically. The
Board has released some detailed data
for the 2022 Federal Reserve Payments
Study and 2023 Annual Supplement,
and more is expected to be released in
the near future.
The Board has adopted the extension,
without revision, of the FR 3066 as
originally proposed.
Board of Governors of the Federal Reserve
System, January 7, 2025.
Benjamin W. McDonough,
Deputy Secretary and Ombuds of the Board.
[FR Doc. 2025–00482 Filed 1–10–25; 8:45 am]
2703
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2025–00491 Filed 1–10–25; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, pursuant to Public Law 92–
463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
DP25–038, Epilepsy Incidence Among
Children in the United States.
Date: March 19, 2025.
Time: 10 a.m.–6 p.m., EDT.
Place: Teleconference/Web
Conference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Catherine Barrett, Ph.D., Scientific
Review Officer, National Center for
Chronic Disease Prevention and Health
Promotion, Centers for Disease Control
and Prevention, 4770 Buford Highway,
Mailstop S106–3, Atlanta, Georgia
30341–3717. Telephone: (404) 718–
7664; Email: CBarrett@cdc.gov.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, pursuant to Public Law 92–
463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
DP25–043, Comprehensive Analysis,
Surveillance, and Statistics Initiative for
Diabetes in the Young (CASSIDY).
Date: March 12, 2025.
Time: 10 a.m.–6 p.m., EDT.
Place: Teleconference/Web
Conference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Natalie Brown, M.P.H., Scientific
Review Officer, National Center for
Chronic Disease Prevention and Health
Promotion, Centers for Disease Control
and Prevention, 4770 Buford Highway,
Mailstop S106–3, Atlanta, Georgia
30341–3717. Telephone: (404) 639–
4601; Email: NBrown3@cdc.gov.
E:\FR\FM\13JAN1.SGM
13JAN1
2704
Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
30341–3717. Telephone: (404) 718–
7664; Email: CBarrett@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2025–00492 Filed 1–10–25; 8:45 am]
BILLING CODE 4163–18–P
[FR Doc. 2025–00488 Filed 1–10–25; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
ddrumheller on DSK120RN23PROD with NOTICES1
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, pursuant to Public Law 92–
463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
DP25–041, Connecting Organizations
and People to Empower Diabetes
Prevention and Treatment
(Connections).
Date: March 11, 2025.
Time: 10 a.m.–6 p.m., EDT.
Place: Teleconference/Web
Conference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Catherine Barrett, Ph.D., Scientific
Review Officer, National Center for
Chronic Disease Prevention and Health
Promotion, Centers for Disease Control
and Prevention, 4770 Buford Highway,
Mailstop S106–3, Atlanta, Georgia
VerDate Sep<11>2014
18:48 Jan 09, 2025
Jkt 265001
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, pursuant to Public Law 92–
463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–OH–24–002, Exploratory/
Developmental Grants on Lifestyle
Medicine Research Related to the World
Trade Center Health Program (R21);
RFA–OH–24–003, Exploratory/
Developmental Grants Related to the
World Trade Center Survivors (R21-No
Applications with Responders
Accepted); RFA–OH–24–004, World
Trade Center Health Program Mentored
Research Scientist Career Development
Award (K01); and RFA–OH–25–001,
Exploratory/Developmental Research for
World Trade Center Health Program
Evidence-based Strategies to Improve
Treatment Effectiveness, Diagnostic
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Practices, and Program Evaluation
(R21).
Dates and Times: February 25, 2025,
9 a.m.–5 p.m., EST; and February 26,
2025, 9 a.m.–12 p.m., EST.
Place: Courtyard by Marriott Atlanta
Decatur Downtown/Emory, 130
Clairemont Avenue, Decatur, Georgia
30030.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Laurel Garrison, M.P.H., Scientific
Review Officer, Office of Extramural
Coordination and Special Projects,
National Institute for Occupational
Safety and Health, Centers for Disease
Control and Prevention, 5555 Ridge
Avenue, Cincinnati, Ohio 45213.
Telephone: (513) 533–8324; Email:
LGarrison@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2025–00487 Filed 1–10–25; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–25–1385]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Characteristics
of Cases of Priority Fungal Diseases’’ to
the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on October 25, 2024, to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
E:\FR\FM\13JAN1.SGM
13JAN1
]]>Agencies
[Federal Register Volume 90, Number 7 (Monday, January 13, 2025)]
[Notices]
[Pages 2703-2704]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00492]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the
following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Office of
Strategic Business Initiatives, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention, pursuant to Public Law 92-
463. The grant applications and the discussions could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the grant applications, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--DP25-043, Comprehensive Analysis,
Surveillance, and Statistics Initiative for Diabetes in the Young
(CASSIDY).
Date: March 12, 2025.
Time: 10 a.m.-6 p.m., EDT.
Place: Teleconference/Web Conference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Natalie Brown, M.P.H., Scientific
Review Officer, National Center for Chronic Disease Prevention and
Health Promotion, Centers for Disease Control and Prevention, 4770
Buford Highway, Mailstop S106-3, Atlanta, Georgia 30341-3717.
Telephone: (404) 639-4601; Email: [email protected].
[[Page 2704]]
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2025-00492 Filed 1-10-25; 8:45 am]
BILLING CODE 4163-18-P
